Menu
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women.

Klatt NR, Cheu R, Birse K, Zevin AS, Perner M, Noël-Romas L, Grobler A, Westmacott G, Xie IY; Butler J; Mansoor L, McKinnon LR, Passmore JS, Abdool Karim Q, Abdool Karim SS, Burgener AA.
Science 2017; 356(6341): 938-945.

Read publication
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide.

Alam SM, Aussedat B, Vohra Y, Meyerhoff RR, Cale EM, Walkowicz WE, Radakovich NA, Anasti K, Armand L, Parks R, Sutherland L, Scearce R, Joyce MG, Pancera M, Druz A, Georgiev IS, Von Holle T, Eaton A, Fox C, Reed SG, Louder M, Bailer RT, Morris L, Abdool Karim SS, Cohen M, Liao H-X, Montefiori DC, Park PK, Fernández-Tejada A, Wiehe K, Santra S, Kepler TB, Saunders KO, Sodroski J, Kwong PD, Mascola JR, Bonsignori M, Moody MA, Danishefsky S, and Haynes BF.
Science Translational Medicine 2017; 9(381): eaai7521.

Read publication
From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa.

Haber N, Tanser F, Bor J, Naidu K, Mutevedzi T, Herbst K, Porter K, Pillay D, Barnighausen T.
Lancet HIV 2017; 4(5):e223-e230.

Read publication
PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study.

Cremin I, McKinnon L, Kimani J, Cherutich P, Gakii G, Muriuki F, Kripke K, Hecht R, Kiragu M, Smith J, Hinsley W, Gelmon L, Hallett TB.
Lancet HIV 2017 May; 4(5):e214-e222.

Read publication
Using mHealth for HIV/TB Treatment Support in Lesotho: Enhancing Patient-Provider Communication in the START Study.

Hirsch-Moverman Y, Daftary A, Yuengling KA, Saito S, Ntoane M, Frederix K, Maama LB, Howard AA.
JAIDS 2017; 74 (Suppl 1):S37-S43.

Read publication
Risk Factors for Incidence of Sexually Transmitted Infections among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003).

Chirenje ZM, Gundacker HM, Richardson B, Rabe L, Gaffoor Z, Nair G, Mirembe BG, Piper JM, Hillier S, Marrazzo J.
Sexually Transmitted Diseases 2017; 44(3):135-140.

Read publication

Centre for the AIDS Programme of Research in South Africa

CAPRISA was created in 2001 and formally established in 2002 under the NIH-funded Comprehensive International Program of Research on AIDS (CIPRA) by five partner institutions; University of KwaZulu-Natal, University of Cape Town, University of Western Cape, National Institute for Communicable Diseases, and Columbia University in New York. CAPRISA is a designated UNAIDS Collaborating Centre for HIV Prevention Research. The main goal of CAPRISA is to undertake globally relevant and locally responsive research that contributes to understanding HIV pathogenesis, prevention and epidemiology as well as the links between tuberculosis and AIDS care.